Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin + fenofibrate versus Pravafenix in mixed dyslipidaemia
2024-514289-38-00Phase 3Authorised
- Sponsor
- SMB Laboratoires
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosuvastatin, fenofibrate, pravastatin and pravastatin + fenofibrate in combined dyslipidaemia and lipid disorder (2 arms), sponsored by SMB Laboratoires. Primary endpoint: Mean percent change in LDL cholesterol. Planned start Feb 2025; status: authorised.
02
Drugs
rosuvastatinfenofibratepravastatinpravastatin + fenofibrate
03
Conditions
combined dyslipidaemialipid disorder
Beyond the preview
Go deeper on 2024-514289-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514289-38-00.